Biogen Stock - $1 billion RayThera deal to expand immunology pipeline

Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 20:52 CET. Details in the imprint.

Biogen Inc. (US09062X1037) has agreed to acquire privately held RayThera in a deal worth up to $1 billion. According to a GlobeNewswire-distributed press release dated 06/18/2026, the transaction will add multiple early-stage immunology assets to Biogen’s pipeline and is expected to close in the third quarter of 2026, subject to regulatory approvals.

RayThera deal details and timing

The RayThera acquisition is structured with an upfront payment plus clinical and regulatory milestones, for a total potential value of up to $1 billion, Biogen said in its press statement distributed via GlobeNewswire on 06/18/2026.

Biogen highlighted that RayThera’s lead immunology asset is poised to enter Phase 1 development, making this a very early-stage pipeline expansion rather than an immediate revenue contributor.

How the agreement fits Biogen’s strategy

The company framed the deal as part of its broader push to deepen its immunology and specialty medicine footprint beyond neurology, diversifying future revenue away from maturing multiple sclerosis therapies.

Against a backdrop of pricing pressure and competition in core franchises, the RayThera assets add optionality but will also increase Biogen’s R&D burden in the near term as Phase 1 programs get under way.

Thursday’s chart and technical picture

On Nasdaq, Biogen shares traded around the mid-$190s on Thursday afternoon Eastern time, with MarketBeat citing a last price of $195.37, down 1.7% on the day as of 02:23 p.m. ET.

At that level, the stock remains below the $200 mark that has acted as a psychological threshold several times in recent months, but above the lows seen during periods of Alzheimer’s pipeline disappointment.

Analyst sentiment and consensus backdrop

Morgan Stanley recently raised its price target on Biogen shares to $224 from $206 while maintaining an Equal Weight rating, according to a summary of analyst actions compiled by Intellectia.

The Equal Weight stance suggests a balanced view: analysts acknowledge upside from the pipeline and cost actions but remain cautious given execution risks and competitive pressures in neurology and immunology.

The product behind the stock

Biogen is still best known for multiple sclerosis therapy Tecfidera, alongside other neurology and rare disease drugs, while it also develops treatments in Alzheimer’s disease and is now adding early-stage immunology candidates through the RayThera acquisition.

Where the stock trades today

The shares of Biogen Inc. (US09062X1037) trade on Nasdaq under the ticker BIIB at $195.37 as of 06/18/2026, 14:23 ET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.